Hospital
Holy Cross Health, INC
Holy Cross Health, INC was paid $5.84M by Medicaid between Jan 2018 and Dec 2024, across 97 billing codes. Its largest line is G0378, Hospital observation service, per hour — 27% of everything it billed.
33Billing provider infoHOLY CROSS HEALTH, INC
SILVER SPRING, MD 20910
SILVER SPRING, MD 20910
33aNPI1669417838assigned 06/19/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.84M
24GClaims163,433
24DCodes billed97
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Maryland
Rank by total paid#8 of 69
Median peer was paid$870K
This provider vs. median6.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,082 | $462K | |
| 2019 | 28,661 | $622K | |
| 2020 | 17,722 | $683K | |
| 2021 | 24,567 | $1.00M | |
| 2022 | 28,566 | $1.25M | |
| 2023 | 22,423 | $1.09M | |
| 2024incomplete | 15,412 | $728K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0378 | Hospital observation service, per hour | 27% | 3,934 | 2,774 | $1.60M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 8,814 | 7,768 | $1.30M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 7,191 | 6,403 | $835K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.4% | 2,486 | 2,210 | $550K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 8.7% | 7,104 | 6,033 | $508K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 9,907 | 7,682 | $97K |
| 84484 | 1.5% | 8,200 | 5,329 | $85K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.4% | 379 | 346 | $79K |
| 71045 | Radiologic examination, chest; single view | 1.3% | 6,444 | 5,514 | $75K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 3,492 | 3,105 | $73K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 16,901 | 11,395 | $68K |
| 36415 | Collection of venous blood by venipuncture | 1.1% | 17,718 | 12,610 | $61K |
85 more codes
| 80053 | Comprehensive metabolic panel | <1% | 8,011 | $52K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,092 | $46K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 601 | $33K |
| 81001 | <1% | 7,319 | $33K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 565 | $29K |
| 84703 | <1% | 2,190 | $22K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,449 | $21K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,929 | $19K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,063 | $18K |
| 82077 | <1% | 492 | $14K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,618 | $14K |
| 87400 | <1% | 264 | $14K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,044 | $12K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 337 | $11K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 922 | $11K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 157 | $11K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,200 | $10K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,323 | $10K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 557 | $9K |
| 83690 | <1% | 2,155 | $9K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 916 | $8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 387 | $8K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 222 | $6K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 32 | $5K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 894 | $5K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 192 | $5K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 113 | $5K |
| J2704 | Injection, propofol, 10 mg | <1% | 834 | $4K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 151 | $4K |
| 80076 | <1% | 951 | $4K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 32 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 875 | $3K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 376 | $3K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 447 | $3K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 633 | $3K |
| 83735 | <1% | 2,077 | $2K | |
| 87581 | <1% | 32 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 457 | $2K |
| 97161 | <1% | 148 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 77 | $2K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 387 | $2K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 83 | $2K |
| 86850 | <1% | 1,081 | $2K | |
| 85027 | <1% | 985 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 238 | $2K |
| 86901 | <1% | 1,458 | $2K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 24 | $2K |
| 87081 | <1% | 64 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 241 | $2K |
| 86900 | <1% | 1,457 | $2K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 467 | $1K |
| 84600 | <1% | 73 | $1K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 315 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 50 | $1K |
| 80061 | Lipid panel | <1% | 391 | $1K |
| 87430 | <1% | 61 | $1K | |
| 99201 | <1% | 14 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 47 | $1K |
| 90686 | <1% | 51 | $919.48 | |
| 72100 | <1% | 38 | $762.78 | |
| 85610 | <1% | 952 | $758.61 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 131 | $737.25 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 633 | $718.36 |
| 97165 | <1% | 49 | $716.00 | |
| 87040 | <1% | 75 | $561.14 | |
| 83605 | <1% | 203 | $559.46 | |
| 82553 | <1% | 143 | $511.66 | |
| 94799 | <1% | 317 | $495.93 | |
| 84702 | <1% | 12 | $390.44 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 86 | $337.23 |
| 83880 | <1% | 162 | $317.59 | |
| 82550 | <1% | 204 | $253.39 | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 15 | $240.52 |
| 87186 | <1% | 51 | $239.95 | |
| 85730 | <1% | 183 | $218.92 | |
| 81003 | <1% | 41 | $127.68 | |
| 84100 | <1% | 629 | $115.07 | |
| 86923 | <1% | 64 | $37.03 | |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 19 | $0.07 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 17 | $0.01 |
| 82248 | 0% | 88 | $0.00 | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 0% | 33 | $0.00 |
| 0250 | 0% | 65 | $0.00 | |
| 87077 | 0% | 13 | $0.00 | |
| 87486 | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKEESE, JULIE (VP & CFO)
| Provider | Location | Paid |
|---|---|---|
| Holy Cross Health, INC. | Germantown, MD | $3.68M |
| Professional Services of Holy Cross | Silver Spring, MD | $3.30M |
| Holy Cross Health, INC. | Silver Spring, MD | $1.32M |
| Holy Cross Hospital Adult Day Care | Silver Spring, MD | $602K |
| Holy Cross Health, INC. | Mitchellville, MD | $123K |
| Trinity Health Mid-Atlantic Medical Group | Darby, PA | $35K |
| Professional Services of Holy Cross: Behavioral Health | Silver Spring, MD | $24K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.